INT71946

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1997
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 1.90
Pain Relevance 2.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Ass1) endoplasmic reticulum (Ass1) nucleus (Ass1)
ligase activity (Ass1) lysosome (Ass1) cytoplasm (Ass1)
Anatomy Link Frequency
plasma 1
fibroblasts 1
skin 1
lungs 1
Ass1 (Mus musculus)
Pain Link Frequency Relevance Heat
Potency 11 99.84 Very High Very High Very High
Calcium channel 2 99.58 Very High Very High Very High
antinociception 10 95.96 Very High Very High Very High
tolerance 13 94.92 High High
fibrosis 66 94.88 High High
cINOD 9 93.68 High High
opioid receptor 8 92.92 High High
agonist 2 90.92 High High
Enkephalin 2 89.16 High High
Intracerebroventricular 1 87.96 High High
Disease Link Frequency Relevance Heat
Reprotox - General 2 2 100.00 Very High Very High Very High
Cancer 118 96.84 Very High Very High Very High
Ovarian Cancer 3 95.52 Very High Very High Very High
Fibrosis 106 94.88 High High
INFLAMMATION 24 75.00 Quite High
Solid Tumor 2 73.60 Quite High
Fabry Disease 28 52.00 Quite High
Breast Cancer 2 50.00 Quite Low
Residual Neoplasm 1 48.08 Quite Low
Lysosome Storage Disease 6 45.76 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It has recently been reported that diltiazem and verapamil, known calcium channel blockers, partially restored mutant glucocerebrosidase folding, trafficking, and enzyme function in patient fibroblasts [32].
Negative_regulation (restored) of fold in fibroblasts associated with calcium channel
1) Confidence 0.41 Published 2010 Journal Current Chemical Genomics Section Body Doc Link PMC2995157 Disease Relevance 0.05 Pain Relevance 0.10
Seven injections of Delta(9)-THC (3.5 days of dosing) resulted in a 12-fold and 36-fold decrease in potency, respectively, while 13 injections of Delta(9)-THC (6.5 days of dosing) produced a 6.2-fold and 9.8-fold degree of tolerance.
Negative_regulation (decrease) of 12-fold associated with reprotox - general 2, tolerance and potency
2) Confidence 0.09 Published 2000 Journal Drug Alcohol Depend Section Abstract Doc Link 10940538 Disease Relevance 0.19 Pain Relevance 0.70
Removal of the naltrexone pellet was followed 24 h later by a decrease of 7.5-fold in the ED50 value of [D-Ala2]deltorphin II, but not that of DPDPE.
Negative_regulation (decrease) of 7.5-fold
3) Confidence 0.03 Published 1998 Journal Eur. J. Pharmacol. Section Abstract Doc Link 9593593 Disease Relevance 0 Pain Relevance 1.04
Similarly, Ctgf siRNA also reduced SPARC expression in skin and lungs (2.9-fold and 1.5-fold reduction with P = 0.044 and 0.102, respectively).


Negative_regulation (reduction) of 2.9-fold in skin
4) Confidence 0.01 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888211 Disease Relevance 0.33 Pain Relevance 0.13
Previous studies from our group have shown that paclitaxel (PTX)-containing PEO-PCL nanoparticles remain stable in vivo, and retain the PEO copolymer (Pluronic) surface layer to increase the circulating half-life and plasma residence time of PTX from a fraction of an hour to 25.3 and 24.0 h, respectively, alongside a nearly 8-fold decrease in total body clearance of the drug.16,21 The concentration of PTX inside the tumor mass of mice-bearing human ovarian carcinoma (SKOV3) xenografts, as a result, was 8.7-fold higher 5 h postinjection as compared to mice treated with paclitaxel solution,16 resulting in enhanced therapeutic efficacy of the nanoparticle formulation over solution PTX, seen by the 63% reduction of final tumor volume.15
Negative_regulation (decrease) of nearly 8-fold in plasma associated with cancer and ovarian cancer
5) Confidence 0.01 Published 2008 Journal Molecular Pharmaceutics Section Body Doc Link PMC2646668 Disease Relevance 0.84 Pain Relevance 0
Similarly, Ctgf siRNA also reduced SPARC expression in skin and lungs (2.9-fold and 1.5-fold reduction with P = 0.044 and 0.102, respectively).


Negative_regulation (reduction) of 2.9-fold in lungs
6) Confidence 0.00 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888211 Disease Relevance 0.33 Pain Relevance 0.13
Comparison of the inhibition of hPGHS-2(R106E) with wild-type hPGHS-2 by 11 structurally diverse selective and nonselective PGHS inhibitors revealed a 0-1000-fold decrease in inhibitory potency on the mutant enzyme.
Negative_regulation (decrease) of 0-1000-fold associated with potency
7) Confidence 0.00 Published 1997 Journal Mol. Pharmacol. Section Abstract Doc Link 9351974 Disease Relevance 0.15 Pain Relevance 0.60

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox